It’s a familiar song, the FDA singing high praise for Epidiolex, a pharmaceutical version of CBD that is less effective than the non-approved whole plant version and costs a ton more. Then there’s the matter of Epidiolex side-effects — everything from elevated liver enzymes and infections to attempts of suicide.
There’s continuing confusion over the legality of cannabidiol oil and fear over potential crackdowns on the product. Recently, however, it seems to me that there are more fallacies circulating in the mainstream.
After years of secretly taking Xanax for sleep, HoneyColony cofounder Maryam Henein was successfully able to kick America’s beloved and addictive benzo to the curb, all with the help of a plant compound, better known as CBD.
DEA has taken yet another swipe at marijuana by amending its already bizarre classification of pot as a Schedule I drug. Now they’re trying to control the plant compound better known as CBD.